Pay in 4 interest-free payments of $28.12 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
PubMed Central PMCID: PMC3263969
S-Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway
Tebaldi M et al
3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
A-770041 vimopan monohydrate PubMed Central PMCID: PMC3263969A 770041 is a potent ans selective LCK inhibitor. Concanavalin A stimulated IL 2 production in whole blood is inhibited by A 770041 with an EC50 of approximately 80 nM. A 770041 is orally bioavailable (F = 34. 1 + 7. 2% at 10 mg kg) and has a t(1 2) of 4. 1 + 0. 1 h. Concanavalin A induced IL 2 production in vivo is inhibited by oral administration of A 770041 (in vivo EC50 = 78 + 28 nM). A 770041 reverses paclitaxel and doxorubicin resistance in